These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9724371)

  • 1. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results.
    Sugawara Y; Braun DK; Kison PV; Russo JE; Zasadny KR; Wahl RL
    Eur J Nucl Med; 1998 Sep; 25(9):1238-43. PubMed ID: 9724371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of FDG PET in patients with cervical cancer.
    Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
    J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?
    Basu S; Chryssikos T; Houseni M; Scot Malay D; Shah J; Zhuang H; Alavi A
    Nucl Med Commun; 2007 Jun; 28(6):465-72. PubMed ID: 17460537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes.
    Mahfouz T; Miceli MH; Saghafifar F; Stroud S; Jones-Jackson L; Walker R; Grazziutti ML; Purnell G; Fassas A; Tricot G; Barlogie B; Anaissie E
    J Clin Oncol; 2005 Nov; 23(31):7857-63. PubMed ID: 16204017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.
    Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
    Radiology; 1998 Mar; 206(3):749-54. PubMed ID: 9494496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection.
    Chacko TK; Zhuang H; Nakhoda KZ; Moussavian B; Alavi A
    Nucl Med Commun; 2003 Jun; 24(6):615-24. PubMed ID: 12766596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection imaging using whole-body FDG-PET.
    Stumpe KD; Dazzi H; Schaffner A; von Schulthess GK
    Eur J Nucl Med; 2000 Jul; 27(7):822-32. PubMed ID: 10952494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
    Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
    J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases.
    Kälicke T; Schmitz A; Risse JH; Arens S; Keller E; Hansis M; Schmitt O; Biersack HJ; Grünwald F
    Eur J Nucl Med; 2000 May; 27(5):524-8. PubMed ID: 10853807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging.
    Zhuang H; Duarte PS; Pourdehand M; Shnier D; Alavi A
    Clin Nucl Med; 2000 Apr; 25(4):281-4. PubMed ID: 10750968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.
    Nakamoto Y; Eisbruch A; Achtyes ED; Sugawara Y; Reynolds KR; Johnston CM; Wahl RL
    Gynecol Oncol; 2002 Feb; 84(2):289-95. PubMed ID: 11812089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diabetic foot: initial experience with 18F-FDG PET/CT.
    Keidar Z; Militianu D; Melamed E; Bar-Shalom R; Israel O
    J Nucl Med; 2005 Mar; 46(3):444-9. PubMed ID: 15750157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
    Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.
    Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
    J Nucl Med; 1998 Dec; 39(12):2145-52. PubMed ID: 9867159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
    Miyauchi T; Wahl RL
    Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.